London, 3 March 2016


Arix Bioscience, formerly Perceptive Bioscience Investments Ltd, has provided capital support to Autolus Limited (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. Alongside Woodford Investment Management LLP, the company has participated in a Series B financing round, providing £40 million of new capital to Autolus.

“We are delighted to be involved with a company with the potential to transform cancer therapy. Autolus is at the cutting-edge of T-cell engineering to create a new generation of programmed T-cells acting as agents to kill tumour cells. Our commitment to Autolus underlines our objective of supporting emerging, innovative companies. Our flexible business strategy enables us to assist companies with finance and practical support whatever their stage of development.”

Dr Joe Anderson, CEO of Arix Bioscience